Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.59 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | F10 | P00742 | 4/20 | 0.56 |
| ▸ | MGLL | Q99685 | 3/20 | 0.55 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.54 |
| ▸ | UBE2M | P61081 | 3/20 | 0.53 |
| ▸ | DCUN1D1 | Q96GG9 | 3/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18464304 | 0.87 | PTPN2 (0.67) | PTPN2PTPN1PTPN6NPC1RAB9A | |
| SCHEMBL28455754 | 0.85 | PTPN1 (0.81) | PTPN2PTPN1PTPN6NPC1RAB9A | |
| SCHEMBL27142167 | 0.83 | PTPN2 (0.61) | PTPN2PTPN1PTPN6NPC1RAB9A | |
| SCHEMBL4290419 | 0.82 | S1PR2 (0.52) | S1PR2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL30019386 | 0.82 | PTPN2 (0.59) | PTPN2PTPN1PTPN6NPC1RAB9A | |
| SCHEMBL13676224 | 0.82 | PTPN2 (0.68) | PTPN2PTPN1PTPN6NPC1RAB9A | |
| SCHEMBL18658290 | 0.81 | UBE2M (0.67) | PTPN2PTPN1PTPN6NPC1RAB9A | |
| SCHEMBL29491079 | 0.81 | UBE2M (0.67) | PTPN2PTPN1PTPN6NPC1RAB9A | |
| SCHEMBL23086091 | 0.81 | STS (0.67) | PTPN2PTPN1PTPN6NPC1RAB9A | |
| SCHEMBL24147974 | 0.81 | PTPN2 (0.67) | PTPN2PTPN1PTPN6NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423043-B2 | 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds | LEXICON PHARMACEUTICALS, INC. (US) | 2008-09-09 | — | — | US | disclosed |
| WO-2006091450-A1 | 4-PIPERIDIN-1-YL-7H-PYRROLO[2,3-D]PYRIMIDINE COMPOUNDS | LEXICON GENETICS INCORPORATED (US) | 2006-08-31 | — | — | WO | disclosed |
| US-20060189638-A1 | kinase inhibitor; proliferative diseases such as cancer, cancer metastasis, inflammation, arthritis, and diseases characterized by abnormal or inappropriate angiogenesis | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189638-A1 | kinase inhibitor; proliferative diseases such as cancer, cancer metastasis, inflammation, arthritis, and diseases characterized by abnormal or inappropriate angiogenesis | CDK4, CDK2, MKI67 | PTPN2 879/4885PTPN1 792/4885PTPN6 931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.